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MSC 6200, Bethesda, MD 20892, USA.The selective deamination of adenosines (A) to inosines (I) in messenger RNAs (mRNAs) can alter the
encoded protein’s amino acid sequence, with often critical consequences on protein stability, local-
ization, and/or function. Insulin-like growth factor-binding protein 7 (IGFBP7) supports cell-adhe-
sion and stimulates ﬁbroblast proliferation with IGF and insulin. It exists in both proteolytically
processed and unprocessed forms with altered cell-extracellular matrix interactions. Here we show
that editing of IGFBP7 transcripts impacts the protein’s susceptibility to proteolytic cleavage, thus
providing a means for a cell to modulate its functionality through A-to-I RNA editing.
Structured summary of protein interactions:
MT-SP1 cleaves IGFBP7 by protease assay (View interaction).
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Posttranscriptional modiﬁcations of protein-coding RNA mole-
cules increase the functionality of the proteome. The selective
deamination of adenosines (A) to inosines (I) in double-stranded
RNA molecules by Adenosine deaminases acting on RNA (ADARs)
changes the sequence with consequences for downstream events,
as the gene expression machinery recognizes inosine as guanosine
[1]. In protein-coding transcripts, the edited codon may convey a
different amino acid compared to its genomically encoded original,
which can affect protein stability, localization, and function. Such
recoding editing was ﬁrst discovered in brain-speciﬁc mRNAs [2–
4]. However, editing is required for the proper development and
functionality of many tissues [5,6].
Insulin-like growth factor-binding protein 7 (IGFBP7) is a se-
creted protein with a N-terminal cysteine-rich domain, a heparin
binding site, a Kazal-type trypsin inhibitor domain and a C-termi-
nal Ig-like type C repeat [7,8]. While early studies elucidated its
mitogenic effects in synergy with IGF and insulin [9], more recentchemical Societies. Published by E
on RNA; IGFBP7, insulin-like
type serine protease 1
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ical Sciences, 45 Center Drivereports illustrate its role as a putative tumor suppressor with func-
tions in apoptosis and senescence [10–12]. IGFBP7 also appears to
be involved in promoting [13] or blocking [14] angiogenesis. In
addition there are reports of increased serum levels of IGFBP7 in
insulin resistant diabetics [15] and that IGFBP7 presents chemo-
kines to extravasating lymphocytes [16].
Bioinformatics screens predicted the mRNA of IGFBP7 to be a
target of ADARs, and indeed it is edited, changing codon 78 from
AGG (arginine) to IGG (glycine), and codon 95 from AAG (lysine)
to AIG (arginine), henceforth termed R78G and K95R, respectively
[17,18]. We hypothesized that the vast functional range of IGFBP7
may in part be facilitated by editing at these two sites, which
would allow for the production of four protein isoforms from one
allele.
Proteolytic processing of IGFBP7 modulates its biological activ-
ity: intact IGFBP7 stimulates growth of DLD-1 colon carcinoma
cells in synergy with insulin/IGF-I, but cleaved IGFBP7 completely
abolishes this growth-stimulatory activity, possibly due to the loss
of insulin/IGF-I binding [19]. Heparin binding to IGFBP7 is de-
creased by proteolysis, while syndecan-1 binding is increased
[19]. Thus, the intact and cleaved forms of IGFBP7 have different
biological activities. Lysine 95 lies directly within the protease
cleavage site, which overlaps with the heparin binding site
(Fig. 1), and we hypothesized that editing would have functional
consequences for the ensuing protein isoforms, speciﬁcally with
regard to proteolytic processing. Here we show that IGFBP7 is edi-
ted at the two sites independently, in a tissue-speciﬁc manner.
Moreover, the resulting protein isoforms are distinctly susceptiblelsevier B.V. All rights reserved.
(a)
(b)
Fig. 1. (a) RNA fold encompassing IGFBP7 editing sites (underlined, bold) within exon 1 predicted by Mfold [17,31]. (b) Schematic representation of functional domains of the
IGFBP7 protein [32]. The approximate positions of the two amino acid changes resulting from RNA editing are indicated. SS = secretion signal (aa1 1–26); HBS = heparin
binding site (aa 89–97) [30]; cleavage = protease processing site at amino acid position 97 [20], PRS = protease recognition site [33].
2314 C. Godfried Sie et al. / FEBS Letters 586 (2012) 2313–2317to proteolytic cleavage by the speciﬁc Membrane-type serine pro-
tease 1 (MT-SP1) [20].
2. Materials and methods
2.1. IGFBP7 RNA editing analysis
Specimen-matched human RNA and gDNA was obtained
from Biochain and RNA was reverse transcribed. An optimized
PCR protocol contained 400nM of each primer (forward
primer 50-GTGCGGCTGCTGCCCTATGTGC-30; reverse primer (cDNA)
50-CGATGACCTCACAGCTCAAGTAC-30; reverse primer (gDNA)
50-CAGGTGCCCTTGCTGACCTG-30), 2U Phire™ Polymerase (NEB),
0.4 mM dNTPs, 1/100 volume cDNA. Cycling conditions were
98 C for 2 min, 35 cycles of 98 C for 10 s, 68 C for 5 s, and
72 C for 8 s, followed by a ﬁnal step of 72 C for 1 min. Products
were subjected to Sanger sequencing (Geneway Research) and
editing levels determined as the ratios of the guanosine divided
by the sum of both adenosine and guanosine signals at the speciﬁc
location in the sequence tracks. For more accurate determination
of editing levels, PCR amplicons were cloned into a pBluescript vec-
tor (Stratagene), individual recombinant clones isolated and puri-
ﬁed plasmid DNA sequenced.
2.2. Recombinant protein expression and puriﬁcation
Full-length IGFBP7 coding sequence in the pCMV6-XL4
expression vector was purchased from Origene. Three isoforms
were created by site-directed mutagenesis, changing codon 78
from arginine (AGG) to glycine (GGG) and/or codon 95 from ly-
sine (AAG) to arginine (AGG). All ORFs were C-terminally tagged
with the HA sequence by PCR ampliﬁcation and ligated into a
pCI-neo vector. These vectors and an empty control were trans-
fected into HEK293 cells using XtremeGene 9 transfection re-
agent (Roche). Stable transfectants were obtained afterselection in MEM medium supplemented with 10% FCS contain-
ing 500 lg/ml G418 for 3 weeks and were maintained in 300 lg/
ml G418 thereafter.
Culture medium of stably transfected HEK293 cell lines was col-
lected, 1/20 volume 20TBS and 1/250 volume EZview Red Anti-
HA Afﬁnity Gel (Sigma) was added and incubated at 4 C with light
agitation for 1 h. Beads were washed 3 with excess cold 1  TBS.
Bound IGFBP7 protein was eluted with 5 volumes of 1  TBS, 0.05%
SDS, 100 lg/ml HA peptide at 38.5 C for 2 h with frequent vor-
texing. Eluates were diluted 1:5 with adjustment buffer
(56.875 mM Tris, 28.75 mMNaCl, 0.01% Tween 20, pH 9) to convert
the elution buffer into the MT-SP1 assay buffer. Diluted samples
were ultraﬁltrated using Amicon Ultra-0.5 Centrifugal ﬁlters (Mil-
lipore) for 15 min at 14,000g at 4 C.
2.3. MT-SP1 proteolytic cleavage assay
100 ng/ll stock solutions of recombinant human matriptase
(MT-SP1, R&D Systems) were prepared in sterile 50 mM Tris, 10%
glycerol, pH 8.0. Relative concentrations of puriﬁed IGFBP7 iso-
forms were estimated from Western blots and input for the prote-
olysis reactions was normalized accordingly. Total reaction volume
was equalized with 1 assay buffer (50 mM Tris, 50 mM NaCl,
0.01% Tween 20, pH 9). MT-SP1 was added to a ﬁnal concentration
of 325 nM (12.5 pg/ll). Proteolysis reactions were allowed to pro-
ceed for 15 min at 25 C, samples were removed at 1, 2, 3, 5, 7.5, 10,
12.5, and 15 min, mixed with SDS sample buffer and boiled for
5 min at 90 C to stop the reaction.
Proteins were separated on a 12% SDS–polyacrylamide gel and
electrophoretically transferred to 0.2 lm nitrocellulose mem-
branes. Membranes were incubated with primary antibody (rabbit
anti-HA, Clontech, 1:300) over night at 4 C and with secondary
antibody (HRP-conjugated anti-rabbit, Promega, 1:25,000) for 2 h
at room temperature. Bound antibody was detected with ECL Plus
(Amersham) and exposure to ﬁlm for 5–30 min.
C. Godfried Sie et al. / FEBS Letters 586 (2012) 2313–2317 2315The band intensities at 27 and 35 kDa were quantiﬁed using Im-
ageJ software (available from http://rsbweb.nih.gov/ij). Percentage
of cleaved IGFBP7 was plotted against time and linear regression
was performed. Slope values denote percentage cleaved as a func-
tion of time (cleavage rate). Cleavage rates were normalized with
respect to substrate input level of the unedited variant and aver-
ages were calculated over four independent experiments.
3. Results
3.1. Tissue-speciﬁc editing patterns of IGFBP7
Editing of IGFBP7 mRNA changes the amino acid encoded by co-
don 78 from arginine to glycine (R78G), and codon 95 from lysine
to arginine (K95R) [17,18] (Fig. 1). Editing of other mRNAs has been
shown to occur in a tissue-speciﬁc manner [21], allowing cells to
modulate proteome functionality according to speciﬁc needs or
in response to external cues. We thus ﬁrst sought to determine
the editing levels of the two sites in IGFBP7’s mRNA in eight differ-
ent human organs. After ampliﬁcation and sequencing of cDNA,
editing levels were estimated from sequence tracks as the ratio
of the guanosine signal over the sum of guanosine and adenosine
signals at that location. Editing at K95R is consistently higher than
at R78G, with a wide range from 6% to 57% for R78G, and 30% to
85% for K95R, which may be indicative of tissue- and site-speciﬁc
regulation of editing (Fig. 2a). Since each cDNA was derived from
a different donor, with the exception of the two brain samples, this
variability could also be due to individual differences rather than
tissue-speciﬁcity. However, Li and co-workers determined IGFBP7
editing levels by deep sequencing and obtained a similar result
for kidney (7% at R78G, 30% at K95R) and various brain regionsFig. 2. (a) Editing levels at R78G (light bars) and K95R (dark bars) were estimated from
determined from peak heights are indicated above the bars. (b) PCR products obtained fro
detailed analysis of transcript versions present in different tissues. Exact percentages of(7–33% at R78G, 46–60% at K95R, respectively) [22]. We thus be-
lieve that the differences in editing seen across the tested human
tissues reﬂect true tissue-speciﬁc editing and not individual
differences.
3.2. Tissue-speciﬁc, site-independent editing in IGFBP7
Editing can produce four transcript versions of IGFBP7. To deter-
mine the distribution of the four versions, IGFBP7 cDNAs from
brain, spleen and heart were cloned into a pBluescript vector and
approximately 100 clones per sample sequenced. Editing leads to
a distinct distribution of transcript variants in the three tissues
(Fig. 2b). Chi-square analysis using a two-way classiﬁcation reveals
no signiﬁcant difference between the editing levels of the two
brain samples. Conversely, when comparing the data from brain
with heart or spleen, respectively, editing levels are signiﬁcantly
different (brain: P < 0.01; spleen: P < 0.025). Comparison between
heart and spleen also shows signiﬁcantly different editing levels
(P-value < 0.001). The consistency of these data with those ob-
tained by sequence track analysis underscores the validity of the
conclusion that editing in IGFBP7 occurs in a tissue-speciﬁc
manner.
Editing at one adenosine is often accompanied by editing at
additional adenosines lying on the same side of the RNA duplex,
which is referred to as coupling [23]. Editing at the R78G could
therefore be dependent on editing at the K95R site. To test this, a
Pearson Chi-square analysis was performed. Coupling between
the two sites is statistically signiﬁcant only in the ﬁrst brain
(P < 0.01) and the heart samples (P << 0.001), but in the second
brain and the spleen samples the percentage of transcripts edited
at both positions simultaneously is statistically insigniﬁcant. Thissequence tracks obtained from eight different human tissues. Editing percentages
m the indicated tissues were cloned, single clones isolated and sequenced, allowing
editing are indicated.
Fig. 3. Proteolytic cleavage rates relative to the unedited variant, normalized to the
substrate input value of the unedited variant as determined by signal intensities.
Displayed are the means and standard deviations of four independent experiments.
A paired T-test shows statistically signiﬁcant differences in cleavage rates of the
K95R (P = 0.001) and the double mutant (P = 0.041) compared to the unedited
variant. K95R and the double mutant are also signiﬁcantly different from each other
(P = 0.046).
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lix, of which there are predicted to be ﬁve between R78G and K95R
[17]. Therefore, mechanical coupling as described by Enstero and
co-workers does not occur here and thus the two sites are edited
independently of each other [23].
3.3. Proteolytic cleavage of IGFBP7 isoforms
Next, we wished to assess whether the changes in amino acid
sequence caused by editing have a functional consequence with re-
gard to proteolytic processing. We thus generated mutated ver-
sions of the IGFBP7 open reading frame (R78G, K95R, doubly
mutated and wild type) and stably transformed HEK293 cells. Each
IGFBP7 variant was C-terminal tagged with the hemagglutinin
(HA) peptide sequence to facilitate puriﬁcation of the protein iso-
forms. The editing competent double-stranded RNA structure of
IGFBP7 is formed entirely by sequences within exon 1 and tran-
scription of the open reading frame of IGFBP7 produces RNA struc-
tures amenable to editing. Editing levels in transcripts of the
recombinant isoforms were determined to be 0% at the R78G and
below 13% at the K95R positions (data not shown).
In vitro proteolysis of IGFBP7-HA isoforms by MT-SP1 results in
27 kDa C-terminal and 8 kDa N-terminal fragments, of which the
full-length and the 27 kDa product are detectable on a Western
blot using anti-HA antibody. The bands of cleaved and uncleaved
protein were quantiﬁed by ImageJ software and cleavage rates
determined over four independent experiments. Compared to the
unedited variant the cleavage efﬁciency of the R78G isoform ap-
pears to be similar, but those of the K95R and double-edited vari-
ants, respectively, are statistically different (Fig. 3). The amino acid
change elicited by editing at the K95R position lies directly within
the protease recognition site, and in all experiments the K95R iso-
form is cleaved less efﬁciently than the other isoforms. The cleav-
age rate of the K95R variant is reduced by more than fourfold
compared to that of the unedited IGFBP7 and the R78G variant.
The double-edited version is cleaved at an intermediate rate.
Cleavage is known to alter the protein’s function and editing is thus
likely to have an impact on IGFBP7 function.
4. Discussion
IGFBP7 is involved in diverse biological functions, from apopto-
sis [10,12], to inhibition or stimulation of growth and angiogenesis
[9,13,14], to stimulation of prostacyclin production by endothelialcells [24] and increased serum levels correlate with insulin-resis-
tance in diabetic men [15]. It associates with type IV collagen
[25] and binds IGFs and insulin [9]. Only one type of post-transla-
tional protein modiﬁcation of IGFB7 is known to date, the N-glyco-
sylation of asparagine 171 [8], and thus regulation of its many
activities through post-translational modiﬁcation alone seems un-
likely. The IGFBP7 pre-mRNA is alternatively spliced, but the func-
tionality of the several splice variants remains to be evaluated [26].
Besides alternative splicing, transcript modiﬁcation by A-to-I RNA
editing might allow expanded functionality of this protein and/or
alter transcript half-life or affect post-transcriptional processes
such as translation efﬁciency.
Here we demonstrate that editing at the K95R site of IGFBP7 re-
sults in signiﬁcant reduction of cleavage by the MT-SP1 protease
in vitro. The reduction in cleavage efﬁciency of the K95R isoform
might be even more pronounced in vivo, where binding to proteo-
glycans and/or IGFs and insulin may compete with recognition and
cleavage of IGFBP7 by MT-SP1. While it remains to be determined
whether inosine-containing IGFBP7 transcripts are processed like
their unedited counterpart in vivo, our assay at least shows that
transcripts with guanosine in place of adenosine at the respective
locations are stable and translated normally. We further show that
editing of IGFBP7 mRNA occurs in a tissue-speciﬁc manner and
that the two ADAR target sites are edited independently of each
other. Such tissue-speciﬁcity is indicative of regulated editing,
especially as editing levels in spleen and lung signiﬁcantly surpass
those in brain, which generally displays the highest levels of edit-
ing [1]. Editing may thus allow a cell to regulate IGFBP7 function
according to speciﬁc needs of the respective tissue, developmental
time-point or in response to external cues.
The intermediate cleavage efﬁciency displayed by the double-
edited isoform is unexpected. Only limited protein structure infor-
mation is available from the related protein IGFBP5 [27,28], whose
N-terminal domain is 57% similar (20% identical) to that of IGFBP7.
Alignment of the homologous regions of IGFBP7 to this structure
shows that both R78G and K95R are in loop-regions, separated
by a b-strand. Since R78G and K95R are presumably in distinct re-
gions of IGFBP7, it is unclear how the amino acid change at R78G in
double-edited isoforms could increase MT-SP1 cleavage rate com-
pared to the K95R single-edited variant. It is conceivable that the
nucleotide change at codon 78 could alter translation rate or efﬁ-
ciency, which in turn might modify protein folding [29]. A change
in protein folding could impact the local IGFBP7 domain structure
and change binding afﬁnity of MT-SP1 to the loop opposite to the
R78G site.
Editing is likely to impact other functions of IGFBP7, as well.
Heparin and heparan sulfates on cell surfaces bind to growth
factors, cytokines, enzymes, and inhibitors, thereby modulating
their biological activities. The motif K89SRKRRKGK97 was identi-
ﬁed as heparin binding site on IGFBP7 [30], so amino acid
changes elicited by editing might modulate cell surface binding.
Also, IGFBP7 was shown to bind to IGFs and together with IGF
and insulin to stimulate the growth of ﬁbroblasts. IGFBP5 binds
IGF-I with a domain homologous to one close to the K95R site in
IGFBP7 [28]. Both binding of IGFBP7 to cell surfaces and IGFs
and insulin could be affected by the amino acid changes elicited
by editing.
A-to-I RNA editing in individual cells generates a pool of differ-
ent IGFBP7 mRNAs, predicted to lead to the production of protein
isoforms that differ not only in their amino acid sequences but also
in their function as shown here. Only a limited number of site-spe-
ciﬁc editing events that effect a functional change in the resulting
protein variant(s) have been identiﬁed so far. Our study shows that
IGFBP7 may exist as functionally different isoforms in various or-
gans and/or disease states, and as such studies involving IGFBP7
should take possible effects of editing into account.
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